

A Charity registered

in England and Wales - charity Number: 1156927

in Scotland - charity Number: SC048960

Annual Report and Financial Statements

Period from 1 June 2018 to 31 May 2019

The trustees are pleased to present their annual report together with the financial statements of the charity for the year ended 31st May 2019.

The financial statements comply with the Charities Act 2011, the Constitution of The Humanimal Trust, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102).



CHAIR'S REPORT

May 2019 marked the Humanimal Trust's fifth anniversary and the start of a landmark year for the charity. As with all such commemorations it offers an opportunity for both celebration and reflection; to be proud of how far we have come and to recommit ourselves to our future challenging goals.

Without doubt we are in a very different place from 2014 – or even 2018. A year is a long time in the charity sector and the last year is no exception. I took over the reins as Chair of Trustees in October 2018, from my esteemed colleague Mike Uglow. Mike continues to sit on the Board and we are truly grateful both for his passion and commitment as Chair and for his valued continuing contributions to the Trust.

During this first year of our new long-term strategy, we feel that important progress has been made towards our long-term objectives. This is especially apparent from our growing profile in both the human and veterinary worlds and among the wider public, who are inspired by our message of reciprocity between human and veterinary medicine. This, however, also remains our greatest challenge.

We continue to have confidence that we are positively growing the charity. We have continued to invest in awareness and engagement, through the Humanimal Hub, the Humanimal Pledge for One Medicine and presence at both public and professional events across the UK. We have steadily been growing support and diversifying income through our new Champions scheme, as well as a new merchandise range, legacies and an investigation of the potential of major gift fundraising. Crucially, we have also been funding research that demonstrates the real impact of a One Medicine approach. All of these are described in more detail below.

We are very proud to announce that we are now registered as a charity in Scotland as well as England and Wales. We look forward to working with friends and colleagues in all parts of Britain in the coming year.

In our 2018 report we set out a number of clear objectives for the year ahead. These are reviewed below, alongside new objectives for 2019/20. The aspiration of our founder, Professor Noel Fitzpatrick, to spearhead collaboration at the clinical coalface for the benefit of both humans and animals, remains our motivation and driving force. One Medicine truly is a concept whose time has come and we are beginning to feel a wave of interest that we must nurture and build upon in the coming months and years.



I would like to give my heartfelt thanks to all those who have offered their time, money and support over the past year: trustees, volunteers, ambassadors, partners and supporters and of course our small, but dedicated team of staff members. We look forward to more exciting times ahead.

Professor Roberto La Ragione

Chair of Trustees



THE YEAR IN REVIEW

"As a small charity with great ambitions, we expect a lot of ourselves. We know that there is much to do if we are to achieve our goals, but the size of the task is dwarfed by the impact we will have if we achieve them."

These words from our 2018 Annual Report stand repetition. We never underestimate the size of the task we have set ourselves but we are more convinced than ever of the importance of our work. Our determination to engage public and professional audiences alike in a deeper commitment to collaboration and reciprocity between the worlds of human and veterinary medicine runs deep. In a world seemingly ever more bent on magnifying our differences, we will continue to focus on what connects us and what we can learn from one another.

The twelve months culminating in our fifth anniversary in May 2019 showed a maturing organisation, continuing the steady growth in size, spend and influence that we have seen in previous years. The first year of our new long term strategy provided a clear sense of direction and a transparent benchmark for future achievements.

In our 2018 report we committed to the following objectives and made the following progress:

- Launch the Humanimal Hub as the physical manifestation of our purpose. The hub will demonstrate the ethos of One Medicine in real time bringing together people with a professional, academic or personal interest to meet, talk, share, learn and collaborate.
 - The online Hub was built and made ready for launch. It is already being tested and populated with a growing content library. It carries event listings and opportunities for collaboration and will be publicly launched in the new financial year.
- Appoint a permanent Science Officer to lead and coordinate our engagement with human and animal medicine communities and develop the Humanimal Trust's voice in academic and scientific networks.
 - Our first Science Officer was appointed in March 2019, but unfortunately family and personal commitments did not allow the role to develop as planned. At the time of writing, we have appointed to the position again. This role is crucial to our future development.
- Launch a five-year fundraising and engagement programme
 - The programme was launched, encompassing a series of awareness and fundraising initiatives and preparation for launch of the Humanimal Pledge for One Medicine. The Pledge, which appears below, provides an opportunity to engage with people from all walks of life and encourage them to show their support for the principle of One Medicine and for the Humanimal Trust. Hundreds of pledges were signed at events during Spring and Summer 2019, starting with the British Small Animal Veterinary Association (BSAVA) Congress in April, even before the official public launch, planned for later in the year.



- Launch the Humanimal Champions supporter programme
 - The champions scheme launched in autumn 2018, providing both new and existing donors with an opportunity to make a regular gift to the charity and show their commitment as an 'Advocate,' 'Champion' or 'Hero'.
- Increase attendance at community events to engage with a wider public audience
 - 2018/2019 saw an increase in attendance at community events and development of the team of volunteer ambassadors, with a view to building the team further in 2019/20, especially in Scotland. Events included a fundraising event in Thruxton, Hampshire, organised by 14-year-old Natasha, a young supporter, and a number of workplace, Women's Institute, and local charity events.
- Increase attendance at educational and professional events to engage with academic and professional audiences
 - o In 2018/2019 we attended the BSAVA Congress in Birmingham, the RCP Conference in Manchester and The VET Festival in Surrey.
- Work with our founder, Noel Fitzpatrick and other trustees to maximise opportunities to promote the Trust during both public appearances and their day to day work
 - During his tour of live shows around the UK, and in his book entitled, 'Listening to the Animals', our founder Noel Fitzpatrick took the opportunity to talk about his commitment to One Medicine and the importance of Humanimal Trust's work. All trustees used their professional networks to engage wider audiences in discussion about collaboration and reciprocity.

Other achievements during the year were as follows:

- Launch of new Humanimal Trust website
- Registration of the charity in Scotland, where we look to build our presence during 2019/20
- Participation in Dogfest™ at Knebworth (Hertfordshire), Tatton Park (Cheshire) and Ashton Court (Bristol)
- Launch of a new range of Humanimal Trust merchandise using our striking new visuals
- Appointment of Hollie Turner as Supporter Relations Coordinator
- Publication of a booklet for scientific audiences about One Medicine
- Development of a range of materials to promote the charity and One Medicine

Ultimately, One Medicine will progress as an accepted approach in both human and veterinary medicine as research built on its principles begins to bear fruit and demonstrate impact for both humans and animals. In 2018/19 Humanimal Trust supported four pieces of work:



Reciprocity in Action - University of Glasgow

The aim of the study was to optimise 'liquid biopsy' technology, a new way of blood sampling in dogs using a process previously developed for humans. Liquid biopsy allows a less invasive process of cancer diagnosis and monitoring response to treatment, as it is easier to repeat than conventional invasive biopsy procedures.

Previous research has shown that DNA is released into the bloodstream as a part of natural processes, and that measuring this cell-free DNA in blood and/or urine has proved useful for human cancer since a tiny part of the cell-free DNA may be released specifically from tumour cells, and is therefore called circulating tumour DNA (ctDNA). This has potential as a clinical blood sampling tool that can be used very precisely to identify the presence of a genetic change such as a cancer specific mutation, and therefore to monitor the disease humans or dogs may have.

The focus of the study was dog bladder tumours which contain a cancer specific mutation in the BRAF gene and have been developing a very sensitive PCR technique to detect the mutated DNA released in tiny amounts in the blood. More robustness in this technique is needed before it can be used clinically, however, a small cohort of bladder cancer specimens have been successfully created, ready for further study and the contribution towards the future development and validation of an alternative, more robust, novel diagnostic platform for canine cancer patients.

Animal Assisted Intervention Research

An online survey of parents and staff was conducted to assess the effect of an animal-assisted intervention (AAI) service at a UK children's university teaching hospital.

Three volunteer handlers with five golden retriever dogs provided AAIs across all eight paediatric wards including day, medical, surgical, oncology and intensive care. Interventions range from meet and greet to assisting nursing care, physiotherapy and occupational therapy, as well as providing distraction during blood taking and other tests including radiology examinations.

Two hundred surveys were completed and there was an overwhelmingly positive response to the service. No concerns were recorded with respect to the presence, cleanliness and behaviour of the dogs. There was a 100% recommendation that similar services should be supported across the UK.

Oncolytic Viro-therapy as a Cancer Treatment - University of Surrey (PhD)

This is a study being undertaken by Nicola Pratt looking at using a virus/viruses to specifically attack cancerous cells rather than chemotherapy to reduce the serious side effects of treatment: The Development and Application of Oncolytic Virus therapy for Treatment of Canine Malignant Tumours

Oncolytic viruses are viruses that preferentially infect and kill cancer cells. For several decades oncolytic virus therapy has been investigated as a new cancer therapy, resulting in a number of viruses including reovirus being approved for the treatment of cancer in humans.



Oncolytic virus therapy has great potential for the treatment of companion animal cancer. However, susceptibility to reovirus varies among cancer types and establishing why (the genetic determinants of tumour cell susceptibility) is crucial to the success of treatment.

The aim of this study is to establish a biomarker associated with susceptibility to reovirus in canine cancers, thereby allowing personalised chemotherapy-sparing oncolytic therapy to treat canine cancer. Understanding susceptibility of different cancers will also help inform human medicine - a One Medicine approach.

Bacteriophages as an Alternative to Antibiotics - University of Surrey (PhD)

Lucy Rhys Davies is developing novel treatments for infections by using viruses that infect bacteria (bacteriophages) to treat bacterial infections, rather than antibiotics: **Understanding Antibiotic Use in Small Animal Medicine & Developing Alternatives.**

This is a multidisciplinary project focusing on the issue of antibiotic resistance in companion animal medicine and the subsequent need for alternatives to antibiotics. The project consists of two parts, designed to combine practical microbiology and health psychology.

The practical part of the project aims to test the viability of bacteriophage therapy as an alternative to antibiotics. Bacteriophages (phages) are small viruses which can infect and kill the bacteria that cause infections. In this project phages are being tested against strains of *E. coli* which have caused infections in canine patients, to determine how successful the phages are at killing the bacteria. As well as testing practical applications of phages, this research involves studying the genetic backgrounds of the phages in order to understand the mechanisms that enable them to kill bacteria, and to assess their safety as alternative antimicrobials.

The aim of the second section of the project is to determine the likelihood of an alternative antimicrobial, such as phage therapy, being accepted into small animal medicine, and to investigate how it can be ensured that these are used appropriately by pinpointing current issues contributing to inappropriate or excessive antibiotic use. This is being researched through surveys and interviews with small animal vets and pet owners in the UK.



Our principal objectives for 2019/20:

- Fund or co-fund at least two further pieces of research that demonstrate One Medicine principles
- Complete public launch of Humanimal Hub and achieve target membership of 250 in year one
- Complete launch of Humanimal Pledge for One Medicine and achieve 5000 sign-ups
- Continue to expand presence at educational and professional events, ensuring balanced presence across both human and veterinary medical events
- Continue to expand presence and talks at community events
- Continue to diversify income streams to ensure sustainable income levels, including growth of the Champion scheme, legacy marketing and development of trust, corporate and major donor streams
- Develop key influencer relationships with a view to building a network of ambassadors in the worlds of human and veterinary medicine

2019/20 is set to be yet another significant year for the Humanimal Trust. The clarity of our annual objectives will be underpinned by ongoing strengthening of our team, infrastructure and supporter base. Above all we will continue to be driven by our ambition for One Medicine to be understood and advocated as integral to the future of human and animal health.



THE HUMANIMAL TRUST IN A NUTSHELL

Who We Are

The Humanimal Trust drives collaboration between vets, doctors and researchers so that all humans and animals benefit from sustainable and equal medical progress but not at the expense of the life of an animal. This is One Medicine. As a charity, we are unique leaders and drivers of this vision in the clinical environment and in public. As individuals, we advocate One Medicine in our professions as well as in our work for the Trust.

History

The Humanimal Trust was established in May 2014 by Professor Noel Fitzpatrick, known globally as a ground-breaking orthopaedic-neuro veterinary surgeon. As a vet he experienced personally the deep divide between human and animal medicine and saw how unfair this was. Frustrated by the lack of opportunities to share what he was learning from day to day practice, or to benefit from relevant learning from human medicine, he decided to create the platform himself. This laid the foundations for the work the Trust does today, removing barriers and seeking to close the divide between human and animal medicine. Since those beginnings, the Trust has started to establish a powerful evidence base and to build understanding of both the principle and the potential of One Medicine. This evidence informs mechanisms to reduce, refine and replace laboratory animal tests; by studying naturally occurring disease, we will make more rapid progress with this. Based in Godalming, Surrey, the Humanimal Trust is a registered charity in England and Wales, influencing worldwide.

Why One Medicine?

One Medicine recognises that progress in both human and veterinary medicine depends on sharing technologies and research that recognise overlapping biological characteristics. As far back as Aristotle in Ancient Greece, convergence between human and animal physiology was a normal part of science. Divergence began in the nineteenth century but an increasing focus on the welfare, rights and conservation of animals in recent times has led to renewed interest. Human and veterinary healthcare can and should advance hand in hand. Technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to be death. A two-way street between human and veterinary medicine is both possible and necessary for humans and animals to benefit equitably from cutting edge advances.



What we do

We increase **awareness** and improve understanding of One Medicine, engaging the public, researchers, doctors, vets and policymakers, showing the evidence and demonstrating the case for change.

We facilitate **collaboration** between human and veterinary medicine, by creating opportunities for professionals to come together.

Through **education**, we inspire everyone to take the One Medicine message forward for the benefit of future generations of both humans and animals.

We fund, facilitate and share the **research** needed to evidence the impact of One Medicine and foster the skills and knowledge needed to make it a reality.

We **influence** legislative, policy and practice change. We work with today's vets, doctors and researchers, funders, legislators and policy makers. We seek to identify those of the future and inspire them with our passion and belief in One Medicine.

How we do it

We make the right conversations happen between the right people. We start them, facilitate them and make sure they continue. We are accessible and inclusive, providing many opportunities for collaboration. We catalyse change.

We invite people to come to our Humanimal Hub – first digital and ultimately physical too – where interaction and learning can take place and humans and animals both benefit from the sharing of knowledge.

We build the evidence base for One Medicine; we listen, we gather, we share. Such evidence is the firm foundation for a credible vision of hope.

We work with the authority and pragmatism that comes from our experience and the confidence that comes from our passion and belief. We work with integrity. We defuse professional confrontation, build bridges and seek to instill a spirit of compassion, respect and mutual benefit.

What we believe

We believe that equitable advances in both human and animal medicine can be achieved more quickly, if there is closer collaboration and mutually beneficial learning. This is One Medicine. We believe and advocate that this will lead to progressively fewer laboratory animal tests until one day they become obsolete.

We believe that technological advances in the diagnosis and analysis of naturally occurring disease mean that for the first time in history the end point of the study of disease does not need to be death.



One Medicine has a very specific focus. It is not the same as One Health, which has a broader purpose including the relationships between humans, animals *and their environments*.

We believe that the world would be fairer and more respectful for humans and animals if One Medicine were more widely understood and delivered.

We are committed to the 3 R's: a reduction in animal testing, refinement and replacement of animal tests wherever possible. We also believe in a fourth R: reciprocity.

We believe a world is possible, where animals and humans benefit equally and at the same time from advances in medicine. This is reciprocity.

We believe in sponsoring only research that helps animals affected by naturally occurring disease – not the use of experimental animal models.

With support and information from the Humanimal Trust, we believe everyone can contribute to One Medicine, through giving, advocating, learning or educating. Anyone can talk to their vet or their doctor about One Medicine.

Our purpose is not to endorse any particular lifestyle, including vegetarian or vegan, nor are we an animal rights organisation. These are personal choices and beliefs and not part of One Medicine.

We believe we all share responsibility for creating a fairer society, with better opportunities to benefit equitably from medical progress for humans and animals. However we believe the greatest responsibility lies with vets, doctors, researchers and scientists worldwide.

We believe that if we miss this opportunity we will all pay the price in wasted time, wasted money and the wasted lives of both humans and animals.



SUMMARY OBJECTIVES AND APPROACH

1. Awareness

We aim to measurably increase public, professional and political awareness, understanding and acceptance of One Medicine.

We will do this through:

- Public awareness marketing and communication
- Influencing key audiences and inspiring hearts and minds
- Publishing and disseminating research and wider discourse around One Medicine
- An engagement approach that creates desire, demonstrates the need for change and generates champions and advocates
- Generating support for One Medicine in general and the Humanimal Trust in particular, through giving, advocating, learning or educating

2. Collaboration

We aim to demonstrably increase collaboration between medical and veterinary professionals, to maximise value and minimise delays in progress.

We will do this through:

- Removing barriers to the sharing of experience and knowledge
- Facilitating collaboration through events, a digital hub and eventually, a physical centre for shared learning
- Encouraging the study of naturally occurring disease in both humans and animals and sharing the data between the professions to avoid wasted time, money and lives for both humans and animals

3. Education

We aim to inspire everyone to take the One Medicine message forward as a credible vision of hope for future generations of humans and animals.

We will do this through:

- Identifying aspiring researchers, scientists, doctors, vets and communicators and actively encouraging their interest in and understanding of One Medicine
- Working with secondary, further and higher education to influence relevant courses so that they encompass One Medicine
- Achieving a paradigm shift in credibility, respect and acceptance of One Medicine not only in the worlds of veterinary and human medicine but also in the wider academic and scientific communities



4. Research

We aim to improve and accelerate the growing understanding of the complex interactions between animal and human biological characteristics, the similarities between them and the opportunities arising from them.

We want to repaint the landscape in which medicine is researched and received; redefining the language of respectful interaction between species at the clinical coalface.

We will do this through:

- Funding research to provide the evidence needed to make One Medicine a reality together with the knowledge and skills to make it possible
- Influencing governments, funders and others to support research into One Medicine

The Humanimal Trust is focusing activities in the following five areas:

- Musculoskeletal Disease
- Neurology & Neurosurgery
- Medical & Surgical Oncology
- Infection & Antibiotic Resistance
- Regenerative Medicine

5. Influence

As the evidence for One Medicine grows, we will continue to share knowledge with policy-makers and politicians to inform better legislation.

We will do this through:

- Active and resolute engagement with today's policy makers, politicians and the academic and research communities
- Seeking to identify those of the future and inspire them with our passion and belief in One Medicine
- Publishing and disseminating publications and briefings



FINANCIAL REVIEW

Income for the year ended 31st May 2019 amounted to £261,998 (£267,539 in 2017/18).

The charity had a planned net deficit of unrestricted income over expenditure for the year of (£45,870) (surplus of £149,802 in 2017/18) resulting in total funds of £228,368 carried forward as at 31st May 2019.

Investment powers and policy

To date, funds have been held on current account at the charity's bank, have not been actively invested and no investment income has been earned. The trustees will monitor the cash balances of the charity and will make decisions as to the appropriateness of this policy going forward.

Reserves Policy and Going Concern

Reserves are required to bridge the gaps between the spending and the receipt of income, and to cover unforeseen circumstances. The charity will normally seek to hold sufficient unrestricted reserves to cover six months of operations, which will enable its work to continue uninterrupted.

The charity has sufficient funds to cover six months of outgoings at the present time and as such the trustees present the accounts on a going concern basis.

REFERENCE AND ADMINISTRATIVE DETAILS

Charity number: Registered in England and Wales, number 1156927

Registered in Scotland, number SC048960

Principal Office: Eashing Barns, Halfway Lane, Eashing, Surrey GU7 2QQ, United Kingdom.

Our advisors: Accountants:

Radford & Sergeant Limited, Building 3, Watchmoor Park, Camberley GU15 3YL.

Bankers:

CAF Bank, Kings Hill Avenue, West Malling, Kent, ME19 4JQ.



Trustees

The trustees serving during the year and since the year-end were as follows:

Prof. Roberto La Ragione (Chair since 11 Oct 2018)	Appointed for three years to August 2019
	Re-appointed for three years to August 2022
Prof. Noel Fitzpatrick	Appointed indefinitely
Ms Dineke Abbing	Appointed for three years to May 2017
	Re-appointed for three years to May 2020
Mr. Mike Uglow	Appointed for three years to November 2018
	(Chair from 14 th Sept 2016 to 11 Oct 2018)
	Re-appointed for three years to November
	2021
Dr. Ben Marshall	Appointed for three years to July 2019
	Re-appointed for three years to July 2022



STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing Document

The Humanimal Trust is a Charitable Incorporated Organisation (CIO) governed by a Constitution dated 6th May 2014 and as last amended 28th May 2019, and is registered as a charity with the Charity Commission. Membership of the CIO is restricted to the serving trustees.

Appointment of trustees

As set out in the Constitution there must be a minimum of three trustees. Apart from the first charity trustees, every trustee must be appointed for a term of three years by a resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

Trustee induction and training

The charity trustees will make available to each new charity trustee, on or before his or her first appointment:

- (a) a copy of the current version of the Constitution; and
- (b) a copy of the CIO's latest Trustees' Annual Report and financial statements.

New trustees undergo an orientation meeting to brief them on: their legal obligations under charity and company law, the Charity Commission guidance on public benefit, and inform them of the content of the Constitution, the committee and decision-making processes, the business plan and recent financial performance of the charity.

Trustees are encouraged to attend appropriate external training events where these will facilitate the undertaking of their role.

Organisation

The board of trustees, which can have up to twelve members, administers the charity and normally meets quarterly at a minimum. The board may from time to time establish sub-committees and three such committees have been active since July 2016: (1) for matters relating to medical and science review, (2) for matters relating to fundraising and marketing, and (3) for matters relating to finance and audit.

Related parties and co-operation with other organisations

None of the trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity and a university or research institution, sponsor, donor or commercialisation partner must be disclosed to the full board of trustees in the same way as any other contractual relationship with a related party.



Pay policy for senior staff

All trustees provide their time freely and no trustee received remuneration. However, trustees did receive reimbursement of expenses incurred on behalf of the charity.

Staff remuneration is set and reviewed by the trustees in accordance with resourcing strategy and financial status.

Risk management

The trustees have a risk management strategy which comprises:

- an annual review of the principal risks and uncertainties that the charity faces;
- the establishment of policies, systems and procedures to mitigate those risks identified in the annual review; and
- the implementation of procedures designed to minimise or manage any potential impact on the charity should those risks materialise.

Financial sustainability remains a notable area of risk as is the case for the charity sector at large. Expenditure is stringently controlled and fundraising efforts are a key focus.

Trustees' responsibilities in relation to the financial statements

The charity trustees are responsible for preparing a trustees' annual report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity law requires the charity trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing the financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with charity law. They are also responsible for safeguarding the assets of the charity and hence taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charitable and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.



By	order	of	the	board	of	trustees
----	-------	----	-----	-------	----	----------

Professor Roberto La Ragione, Chair

Date: 18 December 2019



INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE HUMANIMAL TRUST

I report on the financial statements of The Humanimal Trust for the year ended 31 May 2019 on pages 20 to 26.

Respective responsibilities of trustees and examiner

The charity's trustees are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the Charities Act) and that an independent examination is needed. It is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act) and to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.



Independent examiner's statement

In connection with my examination, no matter has come to my attention:

- 1. which gives me reasonable cause to believe that in any material respect, the requirements:
- to keep accounting records in accordance with section 130 of the Charities Act; and
- to prepare accounts which accord with the accounting records and comply with the accounting requirements of the Charities Act

have not been met; or

2. to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.

Date: 18 December 2019

Kim Swain MA (Oxon) FCA
Radford & Sergeant Limited
Chartered Accountants
Building 3
Watchmoor Park
Camberley
Surrey GU15 3YL



STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE PERIOD FROM 1 JUNE 2018 TO 31 MAY 2019

	Unrestricted Funds	Total Funds	Total Funds
Note			2018
	_	_	£
3	253,500	253,500	263,896
6	5,640	5,640	-
7	2,858	2,858	3,643
	261,998	261,998	267,539
8	74,966	74,966	23,600
8	232,902	232,902	94,137
	307,868	307,868	117,737
	(45,870)	(45,870)	149,802
	274,238	274,238	124,436
	228,368	228,368	274,238
	7	Funds Note 2019 £ 3 253,500 6 5,640 7 2,858 261,998 8 74,966 8 232,902 307,868 (45,870)	Funds Total Funds Note 2019 2019 £ £ £ 3 253,500 253,500 6 5,640 5,640 7 2,858 2,858 261,998 261,998 8 74,966 74,966 8 232,902 232,902 307,868 307,868 307,868 (45,870) (45,870)



BALANCE SHEET AS AT 31 MAY 2019

	Note	Total funds 2019 £	Total funds 2018 £
Fixed assets: Tangible fixed assets	10	3,502	1,019
Current assets: Stock	11	1,356	-
Debtors	12	9,676	6,770
Cash at bank and in hand		277,416	278,673
Total current assets		288,448	285,443
Liabilities:			
Creditors: Amounts falling due within one year	13	63,582	12,224
Net current assets		224,866	273,219
Total net assets		228,368	274,238
The funds of the charity:			
Restricted income funds		-	-
Unrestricted funds		228,368	274,238
Total charity funds		228,368	274,238



NOTES TO THE FINANCIAL STATEMENTS

1 Accounting Policies

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102) and the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

The Humanimal Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) Preparation of the accounts on a going concern basis

The accounts are prepared on a Going Concern basis.

c) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

d) Tangible fixed assets

Tangible fixed assets are stated at their historic cost price less accumulated depreciation. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for use. The asset's residual values, useful lives and depreciation methods are reviewed if there



is an indication of significant change since the last reporting date. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Office equipment - 20% straight line, and Computer equipment - over 3 years.

e) Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Trust's work or for specific research projects being undertaken by the Trust. As at 31 May 2019 all of the Trust's funds are unrestricted.

f) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Expenditure is classified under the following activity headings:

- Expenditure on raising funds; includes the cost of goods sold, payment processing fees, plus fundraising specific materials, supplies and travel.
- Expenditure on charitable activities; includes website design and maintenance, fees of independent examiners, delivery of strategic objective activities.

Governance is included in expenditure on charitable activities. The Trust initially identifies the cost of its support functions. It then identifies those costs which relate to the governance function. Having identified its governance costs, the remaining support costs together with the governance costs are apportioned between the charitable activities undertaken in the year. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

g) Stock

Stock relates to merchandising items and is valued at the lower of cost and net realisable value, after allowance for obsolete and slow moving items.

h) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

i) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Cash in transit is included.

2 Legal status of the Trust

The Trust is a Charitable Incorporated Organisation and has no share capital.



3 Income from donations and legacies

The Trust benefits greatly from the involvement and enthusiastic support of its volunteers. In accordance with FRS 102 and the Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the accounts.

During the year to 31 May 2019 the Trust gratefully received £179,907 from donations online and at events, including £110,000 from a philanthropic foundation. Furthermore the Trust received a generous legacy of £73,593 in March 2019.

Gifts (including Gift Aid reclaimable)
Legacies

2019	2018
£	£
179,907	72,870
73,593	191,026
253,500	263,896

4 Restricted Income

There was no restricted income in the year ended 31st May 2019 (£nil in 2017/18).

Analysis of staff costs, trustee remuneration and expenses, and the cost of key management personnel

Throughout the year the Trust had the continued support from its Development Manager, and a Supporter Relations Coordinator was appointed at the end of April 2019. A Science Officer had been appointed in March 2019 but unfortunately due to personal circumstances this engagement ceased after a few weeks. All other activities of the charity were carried out by volunteers, freelance contractors or consultants and there were no other remunerated members of staff.

The charity trustees were not paid nor received any other benefits from employment with the Trust. No charity trustee received payment for professional or other services supplied to the charity.

Support costs are directly allocated to activities where possible. The remuneration of the Development Manager and the Supporter Relations Coordinator are allocated 40% to raising funds and the balance to charitable activities.

6 Charitable activities

The Trust generated income from merchandise sales during the year of £5,640 (£nil in 2017/18).

7 Other trading activities

The Trust received donations of £2,858 (£3,643 in 2017/18) from sponsored activities where volunteers took on challenges to raise awareness and funds in support of the charity.

8 Expenditure

Principal expenditure included £74,966 to cover the cost of raising funds (£23,600 in 2017/18) and £232,902 towards the cost of delivery of the Trust's charitable objectives (£94,137 in 2017/18). The latter



included £69,835 of continued funding for PhD sponsorship and £49,824 towards the creation of the Humanimal Hub.

Independent examiner's fees	2019	2018
	£	£
Independent examination	2,400	2,400
Accounts preparation	1,080	1,080
	3,480	3,480

9 Corporate Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

10 Tangible fixed assets

	Office equipment	Computer equipment	Totals
	£	£	£
COST			
At 1 June 2018	279	867	1,146
Additions	1,353	1,998	3,351
At 31 May 2019	1,632	2,865	4,497
DEPRECIATION			
At 1 June 2018	7	120	127
Charge for year	267	601	868
At 31 May 2019	274	721	995
NET BOOK VALUE			
At 31 May 2019	1,358	2,144	3,502
At 31 May 2018	272	747	1,019

11 Stock

	2019	2018
	£	£
Fundraising merchandise	90	-
General merchandise	1,266	_
	1,356	-



12 Debtors

The Debtors balance of £9,676 as at 31 May 2019 largely relates to PhD sponsorship and premises cost prepaid for the month of June 2019 plus Humanimal Hub web hosting cost prepaid for June to November 2019.

Debtors	2019	2018
	£	£
Sundry debtors	1	1
Prepayments	9,675	6,669
	9,676	6,770

13 Creditors

The Creditors balance of £63,582 as at 31 May 2019 was made up of trade creditors and income tax, national insurance and pension contributions due in June 2019, along with accrued cost for services received but not yet billed.

Creditors	2019	2018
	£	£
Trade creditors	16,515	6,679
Taxes	3,086	1,323
Other creditors	427	1
Accrued expenses	43,554	4,221
	63,582	8,109

14 Related Parties

There were no related party transactions during the year.